

Supplementary file

**Reduction of CO<sub>2</sub> with ammonia borane and selective formylation of amines  
in the presence of imidazolium halides.**

A. Skarżyńska, A.M. Trzeciak\*

Table S1. Yield of products **2a** and **3a** in the experiment shown on Fig. 4.

Lp	Time [min, h]	Conversion <b>1a</b> [%]	Yield [%]	
			<b>2a</b>	<b>3a</b>
1	30 min.	2	-	2
2	1 h	12	4	8
3	2 h	16	5	11
4	3 h	17	5	12
5	3 h 20 min.	80	16	64
6	3 h 45 min.	81	23	58
7	4 h	84	22	62
8	5 h	84	21	63

Reaction conditions: 0.02 g NH<sub>3</sub>.BH<sub>3</sub>, 0.25 mmol **1a**, 5 bar CO<sub>2</sub>, 0.6 mL CD<sub>3</sub>CN, 80 °C




Figure S1.  $^1\text{H}$  NMR and  $^{11}\text{B}$  NMR spectra for the reaction **1a** + AB + [dbim]Cl + CO $_2$  (5 bar) at 80 °C after 2 h.




Figure S2.  $^{11}\text{B}$  NMR spectra of AB + [IL]X +  $\text{CO}_2$  (5 bar) after 2 h at  $80^\circ\text{C}$ ; [IL]X = a) [dbim]Cl, b) [bmim]Br, c) [bmim] $\text{BF}_4$ , d) [bmim] $\text{PF}_6$

## Products characterization

**N-phenylformamide**<sup>1</sup> A mixture of two rotamers in a ratio of ca 1:1.  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ): major rotamer (51%)  $\delta$  8.37 (ws, 1H), 7.32 (t,  $J = 7.9$  Hz, 2H), 7.13 (t,  $J = 7.4$  Hz, 1H), 7.05 (d,  $J = 7.5$  Hz, 2H) ppm; minor rotamer (49%)  $\delta$  8.66 (d,  $J = 11.4$  Hz, 1H), 7.52 (d,  $J = 7.5$  Hz, 2H), 7.35 (t,  $J = 7.9$  Hz, 2H), 7.18 (t,  $J = 7.4$  Hz, 1H) ppm;  $^{13}\text{C}\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  169.5, 129.8, 129.2,  $\delta$  126.3, 122.1, 119.9, 119.0 ppm; GC-MS:  $\text{C}_7\text{H}_7\text{NO}$ ,  $M = 121.1$  m/z (%): 121 (100), 93 (99), 66 (85), 51 (15), 39 (40).

**N-benzylformamide**<sup>2</sup> A mixture of two rotamers in a ratio of ca 13:1.  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.27 (ws, 1H), 8.20 (d,  $J = 12$  Hz, 0.1H), 7.34-7.28 (m, 6.2), 4.49 (d,  $J = 5.9$  Hz, 2.2H), 4.42 (d,  $J = 6.4$  Hz, 0.3H) ppm;  $^{13}\text{C}\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  160.9, 137.6, 129.1, 128.91, 128.1, 127.9, 127.9, 127.0, 42.3 ppm; GC-MS:  $\text{C}_8\text{H}_9\text{NO}$ ,  $M = 135.2$  m/z (%): 135 (100), 106 (42), 91 (48), 77 (37), 51 (33), 39 (18).

**N-o-tolylformamide**<sup>2</sup> A mixture of two rotamers in a ratio of ca 2:1.  $^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ )  $\delta$  8.53 (d,  $J = 11.3$  Hz, 1H), 8.44 (ws, 0.51H), 7.90 (d,  $J = 7.9$  Hz, 0.6H), 7.20 (m, 3.86H), 7.14 (t,  $J = 6.2$  Hz, 2.4H), 7.08 (t,  $J = 7.8$  Hz, 0.5H), 2.27 (ws, 6H) ppm;  $^{13}\text{C}\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ )  $\delta$  162.8, 131.4, 130.7, 129.4, 127.3, 127.0, 126.1, 125.6, 123.0, 120.5, 17.8, 17.7 ppm; GC-MS:  $\text{C}_8\text{H}_9\text{NO}$ ,  $M = 135.2$  m/z (%): 135 (38), 106 (100), 77 (27), 51 (15), 39 (15).

<sup>1</sup> Siddique M., Boity B., Rit A., *Organometallics*, **2023**, 42, 1395-1403.

<sup>2</sup> Shirvani G., Shokravi A., Amini M., Saemian N., *J Label Compd Radiopharm.*, **2017**, 60 130–134.

**N-(3-chlorophenyl)formamide**<sup>3</sup> A mixture of two rotamers in a ratio of ca 3:1. **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)** major rotamer (62%) δ 8.37 (s, 1.6H), 7.65 (t, *J* = 9 Hz, 1.5H), 7.37 (d, *J* = 8.5 Hz, 1.9H), 7.11 (d, *J* = 8.0 Hz, 1.5H), 7.12 (d, *J* = 8.3 Hz, 2.3H) ppm, minor rotamer (38%) δ 8.66 (d, *J* = 11.3 Hz, 1.6H), 7.28-7.26 (m, 1.65H), 7.07 (t, *J* = 2 Hz, 1.6H), 6.94 (d, *J* = 8.7 Hz, 1.05H) ppm; **<sup>13</sup>C{<sup>1</sup>H} (125 MHz, CDCl<sub>3</sub>)** δ 158.8, 134.9, 131.1, 130.2, 125.5, 125.0, 120.1, 119.0, 117.9, 116.9 ppm; **GC-MS:** C<sub>7</sub>H<sub>6</sub>ClNO, *M* = 156.6 m/z (%): 157 (22), 155 (67), 127 (100), 100 (23), 92 (38), 73 (12), 65 (54), 50 (10), 39 (22).

**N-(4-chlorophenyl)formamide**<sup>1</sup>: A mixture of two rotamers in a ratio of ca 3:2. **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)**: major rotamer (64%), δ 8.36 (ws, 1.8H), 7.47 (d, *J* = 9 Hz, 3.8H), 7.29 (d, *J* = 9 Hz, 3.9H) ppm; minor rotamer (36%) δ 8.63 (d, *J* = 11 Hz, 1H), 7.31 (d, *J* = 9 Hz, 2.7H), 7.0 (d, *J* = 9 Hz, 2.1H) ppm; **<sup>13</sup>C{<sup>1</sup>H} (125 MHz, CDCl<sub>3</sub>)** major rotamer δ 158.7, 129.2, 121.1 ppm, minor rotamer δ 161.9, 129.9, 120.2 ppm; **GC-MS:** C<sub>7</sub>H<sub>6</sub>ClNO, *M* = 156.6 m/z (%): 155 (61), 127 (100), 99 (29), 92 (37), 73 (22), 65 (52), 50 (14), 39 (25).

**benzoxazole** **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)**: δ ppm: 8.08 (s, 1H), 7.78 (d, *J* = 10 Hz, 1H), 7.56 (d, *J* = 10 Hz, 1H), 7.37 (m, 2H); **GC-MS:** C<sub>7</sub>H<sub>5</sub>NO, *M* = 119.04 m/z (%): 119.04 (100), 120.04 (7.7).

**N,N-dihexylformamide**<sup>4</sup> **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)**: δ <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.75 (s, 1H), 7.98 (s, 1H), 4.22 (t, *J* = 7.2 Hz, 4H), 3.23 (m, 2H), 3.14 (t, *J* = 7.1 Hz, 2H), 1.82 (m, 4H), 1.48 (m, 4H), 1.33 (m, 4H), 1.24 (s, 14H), 0.90 (t, *J* = 7.3 Hz, 6H), 0.83 (m, 6H) ppm; **GC-MS:** C<sub>13</sub>H<sub>27</sub>NO, *M* = 213.3 m/z (%): 213 (2), 142 (88), 72 (100), 43 (35), 43 (35), 41 (26).

**benzimidazole** **<sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>CN)**: δ 8.04 (s, 1H, NCHN), 7.53 (m, 2H, Ph), 7.03 (m, 2H, Ph). **<sup>13</sup>C{<sup>1</sup>H} NMR (125 MHz, CD<sub>3</sub>CN)** 141.3, 122, 119.5, 115.4, 109.8. **GC-MS:** C<sub>7</sub>H<sub>6</sub>N<sub>2</sub>, *M* = 118.1 m/z (%): 118 (100), 91 (40), 63 (20).

**N,N-diethylformamide**<sup>5</sup> **<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)**: δ 8.07 (s, 1H), 3.35 (q, *J* = 7.0 Hz, 2H), 3.26 (q, *J* = 7.0 Hz, 2H), 1.18 (t, *J* = 7.0 Hz, 3H), 1.12 (t, *J* = 7.0 Hz, 3H) ppm; **<sup>13</sup>C{<sup>1</sup>H} NMR (125 MHz, CDCl<sub>3</sub>)** δ 162.3, 41.9, 36.6, δ 14.9, 12.8, ppm; **GC-MS:** C<sub>7</sub>H<sub>7</sub>NO, *M* = 101.15 m/z (%): 101 (46), 86 (25), 72 (15), 58 (100), 44 (67).

The signals marked on spectra with \*correspond to the CH<sub>3</sub>COOC<sub>2</sub>H<sub>5</sub> signals, used in purification process.

<sup>3</sup> Wei Y., Wu J., Xue D., Wang C., Liu Z., Zhang Z., Chen G., Xiao J., *Synlett* **2014**, 25, 1295-1298.

<sup>4</sup> Yu X., Yang Z., Guo S., Liu Z., Zhang H., Yu B., Zhaoa Y., Liu Z., *Chem. Commun.*, **2018**, 54, 7633-7636.

<sup>5</sup> Z Song, J. Liu, S. Xing, X. Shao, J. Li, J. Peng, Y. Bai, *Org. Biomol. Chem.*, **2023**, 21, 832-837.




Figure 1.  $^1\text{H}$  NMR spectrum for N-phenylformamide




Figure 2.  $^{13}\text{C}\{^1\text{H}\}$  NMR spectrum for N-phenylformamide




Figure 3.  $^1\text{H}$  NMR spectrum for N-benzylformamide




Figure 4.  $^{13}\text{C}\{^1\text{H}\}$  NMR spectrum for N-benzylformamide




Figure 5. <sup>1</sup>H NMR spectrum for N-o-tolylformamide




Figure 6. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum for N-o-tolylformamide




Figure 7.  $^1\text{H}$  NMR spectrum for N-(3-chlorophenyl)formamide




Figure 8.  $^{13}\text{C}\{^1\text{H}\}$  NMR spectrum for N-(3-chlorophenyl)formamide






Figure 9. <sup>1</sup>H NMR spectrum for N-(4-chlorophenyl)formamide




Figure 10. <sup>13</sup>C{<sup>1</sup>H} NMR spectrum for N-(4-chlorophenyl)formamide




Figure 11.  $^1\text{H}$  NMR spectrum for benzoxazole




Figure 12.  $^1\text{H}$  NMR spectrum for benzimidazole.




Figure 13.  $^{13}\text{C}$  NMR spectrum for benzimidazole.




Figure 14.  $^1\text{H}$  NMR spectrum for dihexylamine.




Figure 15.  $^1\text{H}$  NMR spectrum for diethylformamide.




Figure 16.  $^{13}\text{C}\{^1\text{H}\}$  NMR spectrum for diethylformamide.